Back to search

Article

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development

2019-08-01

Abstract excerpt

Abstract Alzheimer's disease (AD) is still an incurable neurodegenerative disease that causes dementia. AD changes the brain function that, over time, impairs memory and diminishes judgment and reasoning ability. Pathophysiology of AD is complex. Till now the cause of AD remains unknown, but risk factors include family history and genetic predisposition. The drugs previously approved for AD treatment do not modify...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
96a3ce0b-d11b-5763-8297-e44080010342
DOI
10.1055/s-0039-1698405
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug DevelopmentDOI 10.1055/s-0039-1698405
Amyloid β-peptide and Alzheimer's disease.Semantic proximity
Disease‐modifying therapies in Alzheimer's diseaseSemantic proximity
Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.Semantic proximity
Novel Therapeutic Strategies for DementiaSemantic proximity
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseSemantic proximity
Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?Semantic proximity
Therapeutic targets for Alzheimer's disease.Semantic proximity
The Alzheimer’s disease drug development landscapeSemantic proximity
Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer’s DiseaseSemantic proximity
Exploring the therapeutic potential of natural compounds for Alzheimer's disease: Mechanisms of action and pharmacological propertiesSemantic proximity
Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s diseaseSemantic proximity
A rationally designed small molecule for identifying an in vivo link between metal–amyloid-β complexes and the pathogenesis of Alzheimer's diseaseSemantic proximity
Select a neighboring publication to make it the new centre.